623 related articles for article (PubMed ID: 7926289)
1. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
2. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.
Oakes ND; Camilleri S; Furler SM; Chisholm DJ; Kraegen EW
Metabolism; 1997 Aug; 46(8):935-42. PubMed ID: 9258278
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
4. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
[TBL] [Abstract][Full Text] [Related]
5. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Muurling M; Mensink RP; Pijl H; Romijn JA; Havekes LM; Voshol PJ
Metabolism; 2003 Aug; 52(8):1078-83. PubMed ID: 12898477
[TBL] [Abstract][Full Text] [Related]
7. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding.
Oakes ND; Cooney GJ; Camilleri S; Chisholm DJ; Kraegen EW
Diabetes; 1997 Nov; 46(11):1768-74. PubMed ID: 9356024
[TBL] [Abstract][Full Text] [Related]
9. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
[TBL] [Abstract][Full Text] [Related]
10. Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.
Storlien LH; Thorburn AW; Smythe GA; Jenkins AB; Chisholm DJ; Kraegen EW
Diabetes; 1989 Apr; 38(4):499-503. PubMed ID: 2647557
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].
Zhao WH; Xiao JZ; Yang WY; Wang N; Wang X; Chen XP; Bu S
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3074-8. PubMed ID: 16324411
[TBL] [Abstract][Full Text] [Related]
12. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
Seböková E; Kürthy M; Mogyorosi T; Nagy K; Demcáková E; Ukropec J; Koranyi L; Klimes I
Ann N Y Acad Sci; 2002 Jun; 967():424-30. PubMed ID: 12079870
[TBL] [Abstract][Full Text] [Related]
14. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats.
Storlien LH; James DE; Burleigh KM; Chisholm DJ; Kraegen EW
Am J Physiol; 1986 Nov; 251(5 Pt 1):E576-83. PubMed ID: 3535532
[TBL] [Abstract][Full Text] [Related]
15. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats.
Iglesias MA; Ye JM; Frangioudakis G; Saha AK; Tomas E; Ruderman NB; Cooney GJ; Kraegen EW
Diabetes; 2002 Oct; 51(10):2886-94. PubMed ID: 12351423
[TBL] [Abstract][Full Text] [Related]
16. Effects of glycogen stores and non-esterified fatty acid availability on insulin-stimulated glucose metabolism and tissue pyruvate dehydrogenase activity in the rat.
Kruszynska YT; McCormack JG; McIntyre N
Diabetologia; 1991 Apr; 34(4):205-11. PubMed ID: 2065855
[TBL] [Abstract][Full Text] [Related]
17. Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats.
Hettiarachchi M; Chalkley S; Furler SM; Choong YS; Heller M; Cooper GJ; Kraegen EW
Am J Physiol; 1997 Nov; 273(5):E859-67. PubMed ID: 9374670
[TBL] [Abstract][Full Text] [Related]
18. Effects of non-esterified fatty acid availability on insulin stimulated glucose utilisation and tissue pyruvate dehydrogenase activity in the rat.
Kruszynska YT; McCormack JG; McIntyre N
Diabetologia; 1990 Jul; 33(7):396-402. PubMed ID: 2119322
[TBL] [Abstract][Full Text] [Related]
19. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice.
Stevenson RW; Hutson NJ; Krupp MN; Volkmann RA; Holland GF; Eggler JF; Clark DA; McPherson RK; Hall KL; Danbury BH
Diabetes; 1990 Oct; 39(10):1218-27. PubMed ID: 2210074
[TBL] [Abstract][Full Text] [Related]
20. Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat.
Kitakoshi K; Oshida Y; Nakai N; Han YQ; Sato Y
Horm Metab Res; 2001 Jun; 33(6):365-9. PubMed ID: 11456287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
